WVE   $15.31  4.79% Market Closed After Close 15.21 -0.65%

WAVE Life Sciences Ltd
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-09 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish weakening to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-04 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-03 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-08-02 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.


Current temperature: 6.06
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 18.70
Mean unverified/preliminary 18.70 / 18.70
Target Price Low / High 7.00 / 22.00
Median / STD DEV 19.50 / 4.57
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None None None
stoch None None None
ma20 Sell Sell None
ma50 ActivelyBuy None None
ma100 Sell Sell Sell
Candlestick PatternOct. 16, 2024 Bearish Ladder - pattern is a made up of five candlesticks. Pattern appears on a uptrend. Three strong white candlesticks follows by the fourth white candlestick closes also higher but has a long lower shadow. The fifth day is a strong black with an open below the previous day’s body. Considered to be a bearish reversal pattern.
ISIN SG9999014716
ceo Dr. Paul B. Bolno M.B.A., M.D.
Website https://www.wavelifesciences.com
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.